Literature DB >> 21696956

A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.

Melissa M Kemp1, Qiu Wang, Jason H Fuller, Nathan West, Nicole M Martinez, Elizabeth M Morse, Michel Weïwer, Stuart L Schreiber, James E Bradner, Angela N Koehler.   

Abstract

Histone deacetylases (HDACs) are enzymes involved in many important biological functions. They have been linked to a variety of cancers, psychiatric disorders, and other diseases. Since small molecules can serve as probes to study the relevant biological roles of HDACs, novel scaffolds are necessary to develop more efficient, selective drug candidates. Screening libraries of molecules may yield structurally diverse probes that bind these enzymes and modulate their functions in cells. Here we report a small molecule with a novel hydroxy-pyrimidine scaffold that inhibits multiple HDAC enzymes and modulates acetylation levels in cells. Analogs were synthesized in an effort to evaluate structure-activity relationships.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21696956      PMCID: PMC3248787          DOI: 10.1016/j.bmcl.2011.05.098

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  33 in total

Review 1.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

2.  Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.

Authors:  Jim P Dompierre; Juliette D Godin; Bénédicte C Charrin; Fabrice P Cordelières; Stephen J King; Sandrine Humbert; Frédéric Saudou
Journal:  J Neurosci       Date:  2007-03-28       Impact factor: 6.167

3.  A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.

Authors:  Yufeng Chen; Miriam Lopez-Sanchez; Doris N Savoy; Daniel D Billadeau; Geoffrey S Dow; Alan P Kozikowski
Journal:  J Med Chem       Date:  2008-06-26       Impact factor: 7.446

4.  Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.

Authors:  Kyle V Butler; Jay Kalin; Camille Brochier; Guilio Vistoli; Brett Langley; Alan P Kozikowski
Journal:  J Am Chem Soc       Date:  2010-08-11       Impact factor: 15.419

Review 5.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

6.  Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases.

Authors:  Alastair D G Donald; Vanessa L Clark; Sanjay Patel; Francesca A Day; Martin G Rowlands; Judata Wibata; Lindsay Stimson; Anthea Hardcastle; Sue A Eccles; Deborah McNamara; Lindsey A Needham; Florence I Raynaud; Wynne Aherne; David F Moffat
Journal:  Bioorg Med Chem Lett       Date:  2010-09-21       Impact factor: 2.823

7.  Structural biasing elements for in-cell histone deacetylase paralog selectivity.

Authors:  Jason C Wong; Roger Hong; Stuart L Schreiber
Journal:  J Am Chem Soc       Date:  2003-05-14       Impact factor: 15.419

Review 8.  Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.

Authors:  Jiahuai Tan; Shundong Cang; Yuehua Ma; Richard L Petrillo; Delong Liu
Journal:  J Hematol Oncol       Date:  2010-02-04       Impact factor: 17.388

9.  A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p.

Authors:  J Taunton; C A Hassig; S L Schreiber
Journal:  Science       Date:  1996-04-19       Impact factor: 47.728

10.  Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.

Authors:  Alan P Kozikowski; Subhasish Tapadar; Doris N Luchini; Ki Hwan Kim; Daniel D Billadeau
Journal:  J Med Chem       Date:  2008-07-22       Impact factor: 7.446

View more
  5 in total

1.  Uracil as a Zn-Binding Bioisostere of the Allergic Benzenesulfonamide in the Design of Quinoline-Uracil Hybrids as Anticancer Carbonic Anhydrase Inhibitors.

Authors:  Samar A El-Kalyoubi; Ehab S Taher; Tarek S Ibrahim; Mohammed Farrag El-Behairy; Amany M M Al-Mahmoudy
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-19

2.  Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays.

Authors:  Zainab Noor; Noreen Afzal; Sajid Rashid
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

3.  Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.

Authors:  Sung-Hyeok Hong; Sarah E Youbi; S Peter Hong; Bhaskar Kallakury; Phillip Monroe; Hayriye V Erkizan; Julie S Barber-Rotenberg; Peter Houghton; Aykut Üren; Jeffrey A Toretsky
Journal:  Oncotarget       Date:  2014-01-30

Review 4.  The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.

Authors:  Fangyuan Cao; Martijn R H Zwinderman; Frank J Dekker
Journal:  Molecules       Date:  2018-03-02       Impact factor: 4.411

Review 5.  Zinc binding groups for histone deacetylase inhibitors.

Authors:  Lei Zhang; Jian Zhang; Qixiao Jiang; Li Zhang; Weiguo Song
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.